Outcome of Liver Transplantation in Hepatocellular Carcinoma Patients at Siriraj Hospital

Kositamongkol, Prawat; Sanphasitvong, V.; Sirivatanauksorn, Yongyut; Pongpaibul, Ananya; Limsrichamrern, Somchai; Mahawithitwong, Prawej; Asavakarn, S.; Tovikkai, Chutwichai; Dumronggittigule, Wethit

doi:10.1016/j.transproceed.2017.03.047

Cited by 7 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our patients, who were transplanted following deceased donation, we observed similar survival curves for the patients fulfilling the MC or UTS or Asan criteria. Current data on the outcome of patients fulfilling the MC show overall 1-, 3-, and 5-year survival rates of 85-93%, 75-81%, and 68-73%, respectively [14,15]. Our data were comparable to the international data showing 1-, 3-, and 5-year overall survival rates of 82%, 77%, and 69%, respectively, within the MC.…”

Section: Discussionsupporting

confidence: 78%

Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?

et al. 2020

View full text Add to dashboard Cite

Background: The Milan criteria (MC) are widely used for the indication of liver transplantation (LTx) in hepatocellular carcinoma (HCC). Good long-term results have also been reported following LTx for patients exceeding the MC. In this article, we compare the overall and recurrence-free survival of our patients fulfilling and exceeding the MC according to the post-transplant histopathological results. Patients and methods: Data from 120 patients with HCC (22 females and 98 males) were analyzed. The median patient age was 61 years (Q1, Q3 54.7, 65.4), and the median MELD score was 11 (Q1, Q3 8, 15). The median follow-up period was 53 months (Q1, Q3 16.6, 78). Patients were categorized into established criteria (MC, up-to-seven (UTS), Asan criteria, AFP score), and the outcome of the individual groups was compared. Results: Seventy-four of 120 patients fulfilled the MC, 86 patients met the UTS criteria, 85 patients fulfilled the Asan criteria, and 79 patients had an AFP score less than or equal to 2. The 1-and 5-year survival rates of all patients were 76.7% and 55.6%, respectively. In total, 14.2% of all patients (5.4% of patients who met the MC, 7% of patients who met the UTS criteria, 5.9% of patients who met the Asan criteria, and 6.3% of patients who had an AFP score less than 2) experienced recurrence. Conclusions: The outcomes of the patients were comparable to those reported in the current literature. In our population, similar recurrence and survival rates of the patients were noted for patients fulfilling the UTS criteria irrespective of fulfilling or exceeding the MC. Consequently, we consider using UTS criteria as the extended criterion for LTx indication.

show abstract

Section: Discussionsupporting

confidence: 78%

Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The mortality rate of HCC patients was derived from a study estimating the mortality rate of Thai patients with HCC [36]. Since data on the mortality rate of transplanted NASH patients are not available, this study applied the death rate associated with liver transplants and post-liver transplantation in chronic hepatitis B and C patients [37].…”

Section: Transitional Probabilitiesmentioning

confidence: 99%

WITHDRAWN: Economic Burden of Non-Alcoholic Steatohepatitis with Significant Fibrosis in Thailand

Phisalprapa

Prasitwarachot

Kositamongkol

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Non-alcoholic steatohepatitis (NASH) has been recognised as a significant form of chronic liver disease and a common cause of cirrhosis and hepatocellular carcinoma, resulting in a considerable financial burden on healthcare resources. Currently, there is no information regarding the economic burden of NASH in low- and middle-income countries (LMICs). The aim of this study was to estimate the economic burden of NASH in Thailand as a lesson learned for LMICs.Methods: To estimate the healthcare costs and prevalence of NASH with significant fibrosis (fibrosis stage ≥ 2) in the general Thai population, an eleven-state lifetime horizon Markov model with 1-year cycle length was performed. The model comprised Thai population aged 18 years and older. The cohort size was based on Thailand Official Statistic Registration Systems. The incidence of NASH, transitional probabilities, and costs-of-illness were based on previously published literature, including systematic reviews and meta-analyses. The age-specific prevalence of NASH was based on Thai NASH registry data. Costs were expressed in 2019 US Dollars ($). As we undertook analysis from the payer perspective, only direct medical costs were included. All future costs were discounted at an annual rate of 3%. A series of sensitivity analyses were performed.Results: The estimated total number of patients with significant NASH was 2.9 million cases in 2019, based on a NASH prevalence of 5.74%. The total lifetime cost of significant NASH was $15.2 billion ($5,147 per case), representing approximately 3% of the 2019 GDP of Thailand. The probabilistic sensitivity analysis showed that the lifetime costs of significant NASH varied from $11.4 billion to $18.2 billion.Conclusions: The economic burden associated with NASH is substantial in Thailand. This prompts clinicians and policy makers to consider strategies for NASH prevention and management.

show abstract

“…In our patients, who were transplanted following deceased donation, we observed similar survival curves for the patients ful lling the MC or UTS or Asan criteria. Current data on the outcome of patients ful lling the MC show overall 1-, 3-and 5-year survival rates of 85-93%, 75-81%, and 68-73%, respectively 14,15 . Our data were comparable to international data showing 1-, 3-and 5-year overall survival rates of 82%, 77%, and 69%, respectively, within the MC.…”

Section: Discussionmentioning

confidence: 99%

Milan criteria in the MELD era – Is it justifiable to extend the limits for orthotopic liver transplantation?

Morgül

Felgendreff

Kienlein

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The Milan criteria (MC) are widely used for the indication of liver transplantation (LTx) in hepatocellular carcinoma (HCC). Good long-term results have also been reported following LTx for patients exceeding the MC. In this article, we compare the overall and recurrence-free survival of our patients fulfilling and exceeding the MC according to the posttransplant histopathological results.Patients and Methods: Data from 120 patients with HCC (22 females and 98 males) were analyzed. The median patient age was 61 years (Q1, Q3: 54.7, 65.4), and the median MELD score was 11 (Q1, Q3: 8, 15). The median follow-up period was 53 months (Q1, Q3: 16.6, 78). Patients were categorized into established criteria (MC, up-to-seven (UTS), Asan criteria, AFP score), and the outcome of the individual groups was compared.Results: Seventy-four of 120 patients fulfilled the MC, 86 patients met the UTS criteria, 85 patients fulfilled the Asan criteria, and 79 patients had an AFP score less than or equal to 2. The 1- and 5-year survival rates of all patients were 76.7% and 55.6%, respectively. In total, 14.2% of all patients (5.4% of patients who met the MC, 7% of patients who met the UTS criteria, 5.9% of patients who met the Asan criteria, and 6.3% of patients who had an AFP score less than 2) experienced recurrence.Conclusions: The outcomes of the patients were comparable to those reported in the current literature. In our population, similar recurrence and survival rates of the patients were noted for patients fulfilling the UTS criteria irrespective of fulfilling or exceeding the MC. Consequently, we consider using UTS criteria as the extended criterion for LTx indication

show abstract

Outcome of Liver Transplantation in Hepatocellular Carcinoma Patients at Siriraj Hospital

Cited by 7 publications

References 15 publications

Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?

Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?

WITHDRAWN: Economic Burden of Non-Alcoholic Steatohepatitis with Significant Fibrosis in Thailand

Milan criteria in the MELD era – Is it justifiable to extend the limits for orthotopic liver transplantation?

Contact Info

Product

Resources

About